柯富翔醫師於115年04月09-11日參加首爾國際內分泌與代謝大會(2026 SICEM)壁報發表

Sodium-Glucose Cotransporter-2 Inhibitors Reduce Fracture Risk in Patients with COPD and Type 2 Diabetes: A Nationwide Emulated Target Trial。